Debora Williams-Herman

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Med Res Opin 25:569-83. 2009
  2. pmc Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ USA
    BMC Endocr Disord 10:7. 2010
  3. doi Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
    D Williams-Herman
    Department of Clinical Research, Merck Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Diabetes Obes Metab 14:67-76. 2012
  4. doi Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value
    Karl J Krobot
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Curr Med Res Opin 28:1281-7. 2012
  5. doi Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Nir Barzilai
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Curr Med Res Opin 27:1049-58. 2011

Collaborators

Detail Information

Publications6

  1. ncbi Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Med Res Opin 25:569-83. 2009
    ..To assess the 54-week efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control (HbA(1c) 7.5-11%) on diet and exercise...
  2. pmc Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ USA
    BMC Endocr Disord 10:7. 2010
    ..The purpose of the present analysis is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies...
  3. doi Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
    D Williams-Herman
    Department of Clinical Research, Merck Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Diabetes Obes Metab 14:67-76. 2012
    ..To examine the effect of sitagliptin and metformin, alone and in combination, on modelled parameters of β-cell function in patients with type 2 diabetes...
  4. doi Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value
    Karl J Krobot
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Curr Med Res Opin 28:1281-7. 2012
    ..Glycemic efficacy and patient characteristics may influence hypoglycemic events. The present analysis evaluated the risk of hypoglycemia with sitagliptin or glipizide after adjusting for the most recently measured HbA(1c) value...
  5. doi Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Nir Barzilai
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Curr Med Res Opin 27:1049-58. 2011
    ..Type 2 diabetes in the elderly is an important and insufficiently studied public health problem. This study evaluated sitagliptin monotherapy in patients with type 2 diabetes aged ≥ 65 years...